Global Orthobiologics Market Size study & Forecast, by Product Type (Viscosupplements, Bone Growth Factors, Demineralized Bone Matrix (DBM), Synthetic Bone Substitutes, Cellular Allograft, Allografts, and Others), By Application (Spinal Fusion, Maxillofac

Global Orthobiologics Market Size study & Forecast, by Product Type (Viscosupplements, Bone Growth Factors, Demineralized Bone Matrix (DBM), Synthetic Bone Substitutes, Cellular Allograft, Allografts, and Others), By Application (Spinal Fusion, Maxillofacial & Dental, Soft Tissue Repair, Reconstructive & Fracture Surgery, and Others), By End-user (Hospitals & Ambulatory Surgical Centers (ASCs), Specialty Clinics, and Others) and Regional Analysis, 2022-2029

Global Orthobiologics Market is valued at approximately USD 7.63 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 5.4 % over the forecast period 2022-2029. Orthobiologics and regenerative medicines are frequently made from substances naturally present in the body and used to speed the healing process after injuries. These products are used in orthopaedic procedures to speed the healing of injured muscles, ligaments, and tendons as well as broken bones. The key factors driving the market growth are rising cases of Orthopedic Injuries, increasing aging population, and growing sports injuries. Thus, creating demand for the Orthobiologics market during the forecast period.

The primary factors most likely to drive up demand for orthobiologics products are the rapid increase in orthopaedic injuries and musculoskeletal diseases that cause severe physical pain and limited mobility. According to data from the American Academy of Orthopedic Surgeons, more than 6.8 million patients in the U.S. alone visit a doctor each year for orthopaedic injuries. This large patient base that requires orthopaedic injury therapy may drive market expansion during the forecasted period. Also, rising product development by market players propels the market growth forward. For instance, in 2020, Royal Biologics officially launched MAGNUS, a dimethyl sulfoxide (DMSO) free viable cellular bone allograft. Additionally, rising investment in healthcare infrastructure would create a lucrative opportunity for the market during the forecast period. However, the high cost of orthobiologics products stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Orthobiologics Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to introduction of synthetic products by market players and rising adoption of biologics for bone-related injuries & disorders in the region. Whereas, Asia Pacific is also anticipated to exhibit the highest growth rate over the forecast period, owing to factors such as increasing geriatric population, surge in obesity, and growing awareness related to the use of orthobiologics.

Major market players included in this report are:
Medtronic (Ireland)
Zimmer Biomet (U.S.)
DePuy Synthes (Johnson & Johnson Services, Inc.) (U.S.)
Stryker (U.S.)
Anika Therapeutics, Inc. (U.S.)
SeaSpine (U.S.)
Bioventus (U.S.)
RTI Surgical (U.S.)
MTF Biologics (U.S.)
Arthrex, Inc. (U.S.)

Recent Developments in the Market:
 In 2019, Medtronic announced the launch of its Grafton Demineralized Bone Matrix (DBM) in Japan. The spine and orthopaedic treatments use this bone graft.
 In 2021, For its fibergaft bone graft alternatives, which are used in spinal fusion surgeries, Prosidyan received CE mark certifications.

Global Orthobiologics Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Product Type, Application, End-user, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*



The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.
The detailed segments and sub-segment of the market are explained below:

By Product Type:
Viscosupplements
Bone Growth Factors
Demineralized Bone Matrix (DBM)
Synthetic Bone Substitutes
Cellular Allograft
Allografts
Others

By Application:
Spinal Fusion
Maxillofacial & Dental
Soft Tissue Repair
Reconstructive & Fracture Surgery
Others

By End-user:
Hospitals & Ambulatory Surgical Centers (ASCs)
Specialty Clinics
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Medtronic (Ireland)
Zimmer Biomet (U.S.)
DePuy Synthes (Johnson & Johnson Services, Inc.) (U.S.)
Stryker (U.S.)
Anika Therapeutics, Inc. (U.S.)
SeaSpine (U.S.)
Bioventus (U.S.)
RTI Surgical (U.S.)
MTF Biologics (U.S.)
Arthrex, Inc. (U.S.)

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.